Skip to main content
Tuesday 29 July 2025
BlueSky linkedin youtube rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO 2025
    • BIO 2025
    • Axtria Ignite 2025
    • LS Industry Report 2025
    • Frontiers Health 2024
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
BlueSky linkedin youtube rss
Sign in

Exclusive: Frontiers Health - Day one coverage

Views & Analysis
PH HW_ban_800 1
profile-mask
Adam Jeffery
17 November, 2016

data

FacebookXLinkedin
Bookmark this

News
FDA gives the go-ahead to restart Elevidys shipments

FDA gives the go-ahead to restart Elevidys shipments

Sarepta has restarted distribution of its Duchenne muscular dystrophy gene therapy Elevidys, but only for patients who can walk.

R&D
Doctor looking at the data in healthcare setting

From data to impact: How real-world evidence will transform ...

Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Market Access
Bridging research and clinical guidelines
Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

R&D
Deep Dive's research and development 2025 edition out now banner

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research. 

R&D
Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Oncology
Interview at ASCO 2025 with Alison Dziarmaga

Following science to fruition, putting patients first: An AS...

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

Oncology
Life Sciences Industry Report - Part 5 feature image

Life Sciences Industry Report - Oncology

Developments in the oncology space in 2024 brought hope to both industry and patients.

R&D
Evolution Summit 2025 Returns to San Diego promo image
Partner Content

Revolutionising Clinical Trials: Evolution Summit 2025 Retur...

Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers

R&D
Spatial Biology for Drug Development Summit event banner
Partner Content

Welcome to the 3rd Spatial Biology for Drug Development Summ...

Transforming Research & Development with Faster, More Precise Spatial Insights

 
 

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

data

day one

Digital

Frontiers Health

Healthware

innovation. diabetes

Pharma

pharmaophorum

Sandoz

start-up

technology

Category : Views & Analysis / Digital and Social Media

Editor's Picks

  1. AstraZeneca reveals $50bn investment in US facilities
  2. Sanofi to buy UK vaccines developer Vicebio for $1.6bn
  3. RFK Jr formally backs thimerosal ban in US vaccines
  4. GSK forges $12bn alliance with China's Hengrui
  5. UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer
News
FDA gives the go-ahead to restart Elevidys shipments

FDA gives the go-ahead to restart Elevidys shipments

Sarepta has restarted distribution of its Duchenne muscular dystrophy gene therapy Elevidys, but only for patients who can walk.

Market Access
pharmaphorum podcast Episode 178a - Sandra Anderson and Chris Williams, Cencora

The value of a partner, globally and locally

A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • ASCO 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company